Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ZENA
ZENA logo

ZENA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy ZenaTech Inc (ZENA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.420
1 Day change
0.71%
52 Week Range
7.110
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ZenaTech Inc (ZENA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are potential growth opportunities in the drone market, the technical indicators, lack of strong trading signals, and neutral sentiment from hedge funds and insiders suggest a wait-and-see approach is more appropriate.

Technical Analysis

The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 44.911, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.442, with resistance at 1.549 and support at 1.335. Overall, the technical indicators do not strongly support a buy decision.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
2

Positive Catalysts

  • ZenaTech's subsidiary ZenaDrone is pursuing Blue UAS certification for its IQ Quad drone, which could open opportunities in U.S. defense procurement. The rising demand for secure drone solutions in the U.S. government is a potential growth driver.

Neutral/Negative Catalysts

  • The stock's bearish moving averages and neutral RSI indicate a lack of strong upward momentum. Additionally, the stock's historical trend suggests a likelihood of minor declines in the short term (-0.79% in the next day, -0.81% in the next week, -2.43% in the next month).

Financial Performance

No financial data is available for assessment, making it difficult to evaluate the company's recent growth trends or profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for ZENA.

Wall Street analysts forecast ZENA stock price to rise
1 Analyst Rating
Wall Street analysts forecast ZENA stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.410
sliders
Low
7
Averages
7
High
7
Current: 1.410
sliders
Low
7
Averages
7
High
7
Citi
Buy
maintain
$46
AI Analysis
2025-12-22
Reason
Citi
Price Target
$46
AI Analysis
2025-12-22
maintain
Buy
Reason
Citi added an "upside 90-day catalyst watch" on shares of Zenas BioPharma while keeping a Buy rating on the shares with a $46 price target ahead of the early January Phase 3 INDIGO readout in immunoglobulin G4-related disease. Citi believes obexlimab is positioned to show a statistically significant reduction in flares relative to placebo.

People Also Watch